Colin G. Miller, PhD

Colin G. Miller, PhD, FIPEM, CSci, is one of the world’s foremost authorities on the use of medical imaging as an endpoint in pharmaceutical clinical trials. With a career spanning more than three decades — from pioneering ultrasonic attenuation research for hip fracture prediction to designing state-of-the-art imaging core lab strategies for NGF inhibitor programs — Colin brings unmatched scientific depth and operational experience to every engagement.

As founding partner and CEO at Bracken, Colin advises pharmaceutical companies, CROs, and regulatory bodies on imaging strategy, imaging core laboratory selection and oversight, quantitative imaging biomarker development, and reader methodology. His expertise spans osteoporosis, osteoarthritis, oncology, neurology, metabolic disease, and nuclear medicine (PET/SPECT). He has contributed to landmark FDA advisory panels, authored three Springer textbooks on clinical trial imaging, holds three imaging-related patents, and has co-authored guidelines for OARSI, STAIR, and the Radiology Society of North America.

Clients engage Colin when they need imaging decisions made with scientific rigor, regulatory intelligence, and real-world trial experience — getting it right the first time.